Publications & News

  • Tags

News: Unicyte submits Clinical Trial Application for potentially life-saving therapy

Unicyte submits Clinical Trial Application for potentially life-saving therapy for pediatric patients with urea cycle disorders, setting the stage for patient enrollment in H2 2022 Unicyte AG, a clinical-stage development company innovating the field of regenerative medicine, today announced the submission of a Clinical Trial Application (CTA) in Europe for a Phase 2 trial (reLiver-2) designed to assess the safety and efficacy of its proprietary human liver stem cell (HLSC) therapy, HLSC-001, in pediatric patients with early-onset urea cycle disorders (UCD). HLSC-001 is being evaluated in these patients initially as a bridging therapy prior to liver transplantation with the option and ultimate goal to provide a curative therapy. The company expects to initiate patient enrollment in the second half of